STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has received the Great Place to Work Certification for the second consecutive year in the U.S. and additionally in China, Germany, Singapore, and the United Kingdom. A survey revealed that 85% of employees consider Twist a great workplace, significantly higher than the 57% average. CEO Emily M. Leproust emphasized the importance of company culture and announced the release of their first ESG report to showcase commitment to diversity and inclusion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, SVP of Business Development for Data Storage, will present at the JSNN NanoImpacts 2022 conference from October 13-15, 2022 in Greensboro, NC. He will participate in a panel on October 13 and deliver a keynote on DNA data storage on October 14 at 9:00 AM ET. The conference aims to address advancements in synthetic biology and nanomaterials, following the 2018 SemiSynBio Roadmap.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
conferences
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has partnered with the Australian Research Council Centre of Excellence in Synthetic Biology (CoESB) to provide researchers with access to a wide range of Twist's DNA synthesis products. This collaboration aims to enhance research capabilities and foster the development of sustainable biobased products. Twist's proprietary technology will support the design of novel organisms for transforming agricultural waste into valuable products, contributing to a sustainable economy in Australia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
partnership
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust will present at the Baird 2022 Global Healthcare Conference on September 13th at 2:35 p.m. ET in New York. The presentation will be webcast live, and a replay will be available for 30 days. Twist is a leader in synthetic biology, utilizing a proprietary silicon-based technology to manufacture synthetic DNA for various industries, including healthcare and agriculture. The company's focus includes synthetic genes and NGS preparation tools, with future ambitions in DNA data storage and biologics discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $56.1 million for 3QFY22, reflecting a 60% increase from $35.0 million in the same quarter of fiscal 2021. Total orders soared 53% to $59.7 million. The company raised its revenue guidance to $203 million for fiscal 2022. Despite growth, a net loss of $60.5 million was recorded, translating to $1.08 per share. R&D expenses rose to $36.8 million, while cash reserves stood strong at $527.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Flash Memory Summit from August 2-4, 2022, in Santa Clara, CA. His presentation is scheduled for August 4 from 8:30-9:45 AM PT, focusing on the application of DNA for large-scale data storage solutions. The summit gathers industry leaders to discuss various advancements in data storage technologies. For registration, visit: Flash Memory Summit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
conferences
Rhea-AI Summary

Twist Bioscience (TWST) highlights a critical need for innovative enterprise storage technologies, according to a new white paper. Key points include:

  • Projected storage demand could exceed 25 zettabytes by 2030, outpacing available capacity.
  • Approximately 75% of stored data is 'cold', rarely accessed, and likely never deleted.
  • DNA data storage is proposed as a solution, promising high density, cost efficiency, and sustainability.

The company aims to lead in this space, addressing a projected $7 billion unmet storage demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) and Biotia, Inc. have received an expanded Emergency Use Authorization (EUA) from the FDA for their SARS-CoV-2 Next-Generation Sequencing (NGS) Assay. This authorization enhances COVID-19 patient management by allowing for the identification of specific genomic mutations and viral lineages. Originally developed in 2020 and authorized in March 2021, the assay provides crucial insights into evolving variants like Omicron. The assay’s hybridization capture-based method improves mutation detection, aiding clinicians in treatment decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced that CFO Jim Thorburn and CCO Patrick Finn will host a fireside chat at the UBS Genomics 2.0 and Medtech Innovations Summit on August 9 at 2:00 p.m. PT in Dana Point, California. The event will be webcast live, and a replay will be available for 30 days post-event. Twist Bioscience specializes in synthetic DNA manufacturing using its innovative silicon platform, offering products for various industries including healthcare and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2022 third quarter results on August 5, 2022, before market opening. A conference call will follow at 8:00 a.m. ET for analysts and investors to discuss the results and provide business updates. Twist, known for its innovative synthetic DNA manufacturing on silicon chips, continues to expand its offerings, including synthetic genes and tools for next-generation sequencing. Financial results will be posted on their website prior to the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.94%
Tags
conferences earnings

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $36.19 as of April 4, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.2B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.24B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO